Payment overview · 2025
General Payments
$1,151.06
39 reported records · 22 companies
Healthcare provider profile · identity verified
Daniel J Burdick, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · KIRKLAND, WA · NPI 1073750105
Verified facts
What the public records show
CMS Open Payments records show Daniel J Burdick, MD received $1,151.06 in general payments during 2025 across 39 reported records.
Boston Scientific Corporation accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREXONT as an associated drug or biological on 11358 records involving 3581 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Crexont by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Rytary by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $257.41 | 22.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $120.65 | 10.5% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $120.41 | 10.5% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $91.14 | 7.9% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $53.69 | 4.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.25 | 3.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.16 | 3.8% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $42.95 | 3.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.55 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.96 | 3.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $34.69 | 3.0% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $32.88 | 2.9% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.70 | 2.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.30 | 2.5% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$26.43 | 2.3% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $25.13 | 2.2% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.64 | 2.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.24 | 2.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.06 | 1.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $20.12 | 1.8% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.47 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.23 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,151.06 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $178.06 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $120.41 | 4 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $97.63 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $91.14 | 4 | 2025 |
Source payment records
|
|||||
| Vercise Normalized: vercise |
Device | Boston Scientific Corporation | $79.35 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $60.03 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $44.25 | 2 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $43.16 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.55 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $32.88 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
136 | 19 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | CREXONT open payments reported associated product |
CMS Open Payments — General Payments 11358 supporting records · 3581 recipient NPIs · example record 1220525531 |
Crexont · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
231 | 48 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 992 | 267 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 497 | 131 |
| Rytary | Carbidopa/Levodopa | 231 | 48 |
| Donepezil Hcl | Donepezil Hcl | 174 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 30 |
| Rasagiline Mesylate | Rasagiline Mesylate | 143 | 45 |
| Nuplazid | Pimavanserin Tartrate | 136 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 103 | 34 |
| Midodrine Hcl | Midodrine Hcl | 100 | 17 |
| Gabapentin | Gabapentin | 95 | 30 |
| Amantadine | Amantadine Hcl | 87 | 29 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 85 | 18 |
| Selegiline Hcl | Selegiline Hcl | 80 | 20 |
| Rivastigmine | Rivastigmine Tartrate | 71 | 21 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Sertraline Hcl | Sertraline Hcl | 56 | 16 |
| Entacapone | Entacapone | 55 | 21 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Rivastigmine | Rivastigmine | 54 | 16 |
| Mirtazapine | Mirtazapine | 49 | 12 |
| Propranolol Hcl | Propranolol Hcl | 38 | 17 |
| Gocovri | Amantadine Hcl | 36 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Austedo | Deutetrabenazine | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Galantamine Er | Galantamine Hbr | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Crexont | Carbidopa/Levodopa | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Carbidopa | Carbidopa | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Nourianz | Istradefylline | 12 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,151.06 · 39 records | Boston Scientific Corporation | AMVUTTRA, AUSTEDO XR, BOTOX, BRIUMVI, Dysport, EPIDIOLEX, General - DBS, Hizentra, INBRIJA, INFINITY, KESIMPTA, Leqembi, NUPLAZID, ONGENTYS, QULIPTA, Qelbree, Rystiggo, UPLIZNA, VYALEV, VYEPTI, VYVGART HYTRULO, Vercise, Xeomin | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error